Published in Nursing Home and Elder Business Week, June 19th, 2005
This collaboration is aimed at combining Access' proprietary vitamin B12 oral drug delivery technology with the potential Alzheimer disease treatment drug, Oligotropin (HF0420) owned by U.K.-based biopharmaceutical company Hunter-Fleming, Ltd.
The vitamin B12 oral drug delivery technology utilizes the body's natural transport system for vitamin B12. This receptor-mediated process actively transports vitamin B12 from the gut to the blood stream. Access' scientists have found that the attachment of vitamin B12 to drugs, polymers...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week